BK Technologies Corporation: BK Technologies BKR 5000 Approved by U.S. Department of the Interior
WEST MELBOURNE, FL / ACCESSWIRE / April 1, 2021 / BK Technologies Corporation (NYSE American:BKTI) today announced it has received approval from the U.S. Department of the Interior (DOI) for its BKR 5000 Digital P25 communications technology.
BK President Tim Vitou commented, We are pleased to complement our recent NIFC Fire Approval with the DOI s favorable test results, providing the necessary approval for DOI agency purchases, including high-risk fire and law enforcement use. Our Engineering team provided priority care and assistance to the DOI s technical staff and leadership at the DOI Testing Service Center in Denver. The formal DOI communication noted that the BKR5000 passed on every risk assessment code that is tested. All DOI agencies combined have an estimated 80,000 BK radios deployed across the nation. We are proud to offer our latest communication technology to the DOI fo
BK Technologies BKR 5000 Approved by U S Department of the Interior
theusnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theusnews.com Daily Mail and Mail on Sunday newspapers.
Arizona Researchers Develop Drug Combo to Treat COVID-19
newsmax.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newsmax.com Daily Mail and Mail on Sunday newspapers.
Allarity Therapeutics announces plans to test antiviral activity of stenoparib drug
Allarity Therapeutics of Hørsholm, Denmark, today announced plans to further test the antiviral activity of stenoparib, its PARP inhibitor, against SARS-CoV-2 lineage B.1.1.7, also known as Coronavirus Variant B117 (the British variant ), at the COVID-19 Testing Service Center (CTSC) of Northern Arizona University s Pathogen and Microbiome Institute (PMI), a leading U.S. infectious disease testing center.
The virus variant was labeled Variant of Concern 202012/01 by Public Health England (PHE), an agency of the UK Department of Health and Social Care, in a publication on December 21, 2020, after it was found to have spread rapidly within the UK, and the PHE assessed that this variant has a substantially increased transmissibility compared with other coronavirus variants.
E-Mail
Allarity Therapeutics of Hørsholm, Denmark, today announced plans to further test the antiviral activity of stenoparib, its PARP inhibitor, against SARS-CoV-2 lineage B.1.1.7, also known as Coronavirus Variant B117 (the British variant ), at the COVID-19 Testing Service Center (CTSC) of Northern Arizona University s Pathogen and Microbiome Institute (PMI), a leading U.S. infectious disease testing center.
The virus variant was labelled Variant of Concern 202012/01 by Public Health England (PHE), an agency of the UK Department of Health and Social Care, in a publication on December 21, 2020, after it was found to have spread rapidly within the UK, and the PHE assessed that this variant has a substantially increased transmissibility compared with other coronavirus variants. This variant has also been identified in the U.S. in several states, and the Centers for Disease Control confirms that this variant spreads more easily and quickly than other variants.